For education only · Not medical advice
← All articles
September 2026 Weight & Metabolic 7 min read

Tirzepatide: what it is, and what the trials actually showed

Tirzepatide is one of the very few peptides with a phase 3 programme large enough that most of the interesting questions have real answers, which makes it a good place to practise telling a measured result from a marketing line.

The short answer

  • Tirzepatide is a 39-amino-acid synthetic peptide that activates two gut hormone receptors at once, GIP and GLP-1. It is given as a once-weekly injection under the skin, and it is sold as Mounjaro and Zepbound.
  • Evidence tier: Approved for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea with obesity. Human trials for heart failure with preserved ejection fraction, for MASH with fibrosis, and for delaying type 2 diabetes in people with prediabetes. For “microdosing” there is no evidence at all, which is not a tier so much as the absence of one.
  • In SURMOUNT-1, the largest weight trial, body weight fell 15.0%, 19.5% and 20.9% on the 5, 10 and 15 mg doses over 72 weeks, against 3.1% on placebo.
  • Head to head against semaglutide 2.4 mg, tirzepatide produced a larger change in body weight over the trial period, 20.2% versus 13.7%.
  • The cardiovascular outcome trial compared tirzepatide with another injectable GLP-1 drug, not with placebo, and showed noninferiority rather than superiority.
  • Body weight returns after the drug stops. That is the most consistently replicated finding in the entire programme.

What tirzepatide is

Tirzepatide is a linear 39-amino-acid peptide built on the sequence of native GIP rather than native GLP-1. Three engineering choices give it its long life in the body: two positions carry a non-standard amino acid (Aib) that blocks enzymatic breakdown, a 20-carbon fatty diacid chain is attached through a linker so the molecule binds tightly to albumin, and the tail end is amidated. Its receptor activity is deliberately lopsided. Affinity at the GIP receptor is similar to native GIP, while affinity at the GLP-1 receptor is roughly five-fold lower than native GLP-1, with biased signalling at that receptor. Half-life is about 5 to 6 days in people with overweight or obesity, so steady state arrives after about four weeks.

The GLP-1 half of the mechanism is well understood: glucose-dependent insulin release, suppression of glucagon, slower gastric emptying, and reduced food intake through central pathways. If you want that half in more depth, see how GLP-1 receptor agonists work.

The GIP half is genuinely unresolved. GIP stimulates insulin release in healthy people but its effect is blunted in type 2 diabetes. GIP receptor agonism may act on how fat tissue handles lipid, and it may dampen nausea pathways in the brain, which would help tolerability. But a GIP receptor antagonist under development also causes weight loss, so nobody can currently say which direction of GIP signalling does the work.

What the trials measured

Two phase 3 programmes carry most of the weight. SURPASS studied glycaemic control in type 2 diabetes. SURMOUNT studied body weight in people with obesity or overweight.

In SURPASS-2, tirzepatide lowered A1c by 2.01 to 2.30 percentage points across its doses, against 1.86 points for semaglutide 1 mg.

In SURMOUNT-1, over 72 weeks, weight change was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, against 3.1% on placebo. SURMOUNT-2 repeated the design in people who also had type 2 diabetes, where the effect on every incretin drug is smaller. SURMOUNT-5 was the direct comparison with semaglutide 2.4 mg.

SURMOUNT-OSA measured something other than a number on a scale. In people with moderate-to-severe obstructive sleep apnea and obesity, the apnea-hypopnea index fell by 25.3 events per hour versus 5.3 in the group not using PAP, and by 29.3 versus 5.5 in the group using PAP, at 52 weeks. That trial is the basis for the sleep apnea authorisation.

Two further programmes sit at Human trials and not at approval. SUMMIT, in heart failure with preserved ejection fraction and obesity, reported cardiovascular death or worsening heart failure in 9.9% versus 15.3%, with a small numerical excess of cardiovascular deaths (8 versus 5) that was not statistically meaningful but is worth knowing. SYNERGY-NASH, a phase 2 liver trial, reported MASH resolution in 44% to 62% versus 10% at 52 weeks.

What the cardiovascular trial did and did not show

SURPASS-CVOT is frequently summarised wrongly, so it is worth being precise. It was an active-comparator trial: tirzepatide up to 15 mg against dulaglutide 4.5 mg, over a median of about four years, in people with type 2 diabetes and established atherosclerotic disease. Major adverse cardiovascular events occurred in 12.2% versus 13.1%, a hazard ratio of 0.92. That result met the noninferiority criterion. Superiority was not shown.

Because there was no placebo arm, the trial does not on its own establish that tirzepatide reduces cardiovascular events compared with no incretin therapy. As of September 2026 there is no labelled cardiovascular indication for tirzepatide in the United States.

Stopping, and stepping down

SURMOUNT-4 ran a 36-week lead-in that produced a 20.9% weight reduction, then randomised participants to continue or to switch to placebo. Over the following 52 weeks the placebo group regained 14.0% while those continuing lost a further 5.5%.

SURMOUNT-MAINTAIN, published in 2026, is the first randomised test of a planned step-down. After 60 weeks at the maximum tolerated dose, participants continued that dose, stepped down to the labelled 5 mg dose, or moved to placebo. Weight change from baseline at 112 weeks was 21.9%, 16.6% and 9.9% respectively. Rescue therapy was needed by 8%, 25% and 67% of each group. The honest reading is that a lower labelled maintenance dose holds more than stopping and less than continuing.

Regulatory status as of September 2026

In the United States, Mounjaro is authorised for type 2 diabetes in adults and in patients aged 10 and over, and Zepbound for weight reduction and long-term maintenance and for obstructive sleep apnea with obesity. The class warning about suicidal behaviour and ideation was removed in February 2026 after an FDA class review. Tirzepatide is not FDA-approved for heart failure.

In Canada, Mounjaro is authorised for type 2 diabetes only, with a notice of compliance dated November 2022. Zepbound received its notice of compliance for chronic weight management on 13 May 2025 and for obstructive sleep apnea with obesity on 16 June 2026. There is no Canadian generic tirzepatide. Health Canada advisory RA-81518, dated 21 January 2026, names Mounjaro and Zepbound as the only authorised tirzepatide products, and an advisory of 1 August 2025 listed tirzepatide among unauthorised injectable peptides seized from an online seller. Health Canada’s advisory of 9 April 2026 states that a “research use only” label confers no legal status of its own.

On the compounding question in the United States, FDA’s final determination that the tirzepatide shortage was resolved is dated 19 December 2024. Enforcement discretion ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities. FDA had received more than 730 adverse-event reports for compounded tirzepatide by 31 May 2026.

Under the 2026 WADA rules tirzepatide is not prohibited, but it sits on the 2026 Monitoring Program under “markers of semaglutide and tirzepatide”.

Microdosing has no trial behind it

No randomised trial has tested weekly tirzepatide below the lowest labelled step for any outcome. The 2.5 mg step exists as an initiation dose and is not a maintenance dose. What exists is commentary in Obesity discussing the practice and its evidence gaps, which is not the same thing as a trial. Dose accuracy from partial dialling of a multi-dose pen is also not assured.

Safety, briefly

The common adverse events are gastrointestinal: nausea, diarrhoea, vomiting, constipation, abdominal pain, dyspepsia, reflux, plus injection-site reactions, fatigue and hair loss, mostly during escalation. Label warnings include a boxed warning for thyroid C-cell tumours seen in rats, plus severe gastrointestinal reactions, acute kidney injury from volume depletion, gallbladder disease, pancreatitis, hypoglycaemia when combined with insulin or sulfonylureas, and aspiration risk under anaesthesia. The Canadian monograph of June 2026 added a class precaution for sudden vision loss (NAION).

One label detail is easy to miss: because gastric emptying slows, oral contraceptive exposure falls, so both labels advise a non-oral or additional barrier method for four weeks after starting and after each dose increase.

On body composition, the DXA substudy in SURMOUNT-1 found about 25% of the weight lost was lean mass, which was the same proportion as in the placebo group. For how the broader class compares, see semaglutide versus tirzepatide versus retatrutide and the tirzepatide reference page.

The bottom line

Tirzepatide is one of the best-evidenced peptides in existence, and that cuts both ways: the large effects are real and well measured, and so are the limits. The cardiovascular trial showed noninferiority to another drug rather than superiority, the role of GIP signalling is unresolved, the heart failure and liver findings are not approvals, and the regain data are unambiguous. Everything in this article came from trial reports and product labels, and anything circulating without one of those behind it should be treated as a claim rather than a finding.

Education only. This page is educational. Most compounds referenced are not approved for human use, and a “research use only” label carries no legal status of its own. Nothing here constitutes medical advice, diagnosis, or treatment.

Sources

Peptides 101TirzepatideGLP-1
For education only · Not medical advice